Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemfibrozil and rifampicin drug-drug interaction with SAR442168 (tolebrutinib) in healthy subjects
NCT06064539Phase 1Completed
- Sponsor
- Sanofi
- Start
- May 2020
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tolebrutinib in multiple sclerosis (MS) (2 cohorts), sponsored by Sanofi. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to Last Measurable Concentration and Area Under the Plasma Concentration-Time Curve. Started May 2020; status: completed.
02
Drugs
tolebrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT06064539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06064539.